The SGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The SGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View SGEN Detailed Price Forecast - CNN Money||View SGEN Detailed Summary - Google Finance|
|View SGEN Detailed Summary - Yahoo! Finance||View SGEN Stock Research & Analysis - Zacks.com|
|View SGEN Trends & Analysis - Trade-Ideas||View SGEN Major Holders - Barrons|
|View SGEN Call Transcripts - NASDAQ||View SGEN Breaking News & Analysis - Seeking Alpha|
|View SGEN Annual Report - CompanySpotlight.com||View SGEN OTC Short Report - OTCShortReport.com|
|View SGEN Fundamentals - TradeKing||View SGEN SEC Filings - Bar Chart|
|View Historical Prices for SGEN - The WSJ||View Performance/Total Return for SGEN - Morningstar|
|View the Analyst Estimates for SGEN - MarketWatch||View the Earnings History for SGEN - CNBC|
|View the SGEN Earnings - StockMarketWatch||View SGEN Buy or Sell Recommendations - MacroAxis|
|View the SGEN Bullish Patterns - American Bulls||View SGEN Short Pain Metrics - ShortPainBot.com|
|View SGEN Stock Mentions - StockTwits||View SGEN Stock Mentions - PennyStockTweets|
|View SGEN Stock Mentions - Twitter||View SGEN Investment Forum News - Investor Hub|
|View SGEN Stock Mentions - Yahoo! Message Board||View SGEN Stock Mentions - Seeking Alpha|
|View Insider Transactions for SGEN - SECform4.com||View Insider Transactions for SGEN - Insider Cow|
|View SGEN Major Holdings Summary - CNBC||View Insider Disclosure for SGEN - OTC Markets|
|View Insider Transactions for SGEN - Yahoo! Finance||View Institutional Holdings for SGEN - NASDAQ|
|View SGEN Stock Insight & Charts - FinViz.com||View SGEN Investment Charts - StockCharts.com|
|View SGEN Stock Overview & Charts - BarChart||View SGEN User Generated Charts - Trading View|
Blog Exposure - Seattle Genetics Announces First Patient Dosage in Phase-2 innovaTV 207 Trial for Multiple Solid Tumors
Posted on Monday July 16, 2018
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want access to our free research report on Seattle Genetics, Inc. (NASDAQ: SGEN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SGEN as the Company's latest news hit the wire. On July 12, 2018, the Company announced the dosing of the first patient in the Phase-2 innovaTV 207 clinical trial evaluating the activity, safety, and tolerability of tisotumab vedotin as a monotherapy in selected solid tumors with high Tissue Factor expression. Active-Investors.com is currently working on the research report for BeyondSpring Inc. (NASDAQ: BYSI), which also belongs to the Healthcare sector as the Company Seattle Genetics.
Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering
Posted on Friday July 13, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 12) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Arbutus Biopharma ...
Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
Posted on Thursday July 12, 2018
Seattle Genetics, Inc. (SGEN) today announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial evaluating the activity, safety and tolerability of tisotumab vedotin as monotherapy in selected solid tumors with high Tissue Factor expression. Tissue Factor is overexpressed in a broad range of solid tumors that are associated with a poor prognosis. Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) designed to target the Tissue Factor antigen on the surface of cancer cells and deliver the cell-killing agent monomethyl auristatin E (MMAE) directly inside cancer cells.
Breakfast Technical Briefing on Tetraphase Pharma and Three Other Additional Biotech Stocks
Posted on Thursday July 12, 2018
LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on TTPH sign up now at www.wallstequities.com/registration. Companies in the Biotechnology industry primarily use living organisms or molecular and cellular techniques to provide chemicals, food, and services that meet human needs.